

AMCP Welcomes Senate Introduction of the Medicaid VBPs for Patients (MVP) Act

AMCP applauds [the Senate introduction](#) of the Medicaid VBPs for Patients (MVP) Act ([S. 4204](#)) by Senators Markwayne Mullin (R-OK), Kyrsten Sinema (I-AZ), Tim Scott (R-SC), and Maggie Hassan (D-NH). Introduced in the Senate on April 30, the bipartisan MVP Act will further enhance the use of value-based purchasing arrangements in Medicaid, expanding patient access to novel therapies. The Senate bill accompanies a companion bill ([H.R. 2666](#)), which was introduced in the House of Representatives on April 20, 2023 by Representatives Brett Guthrie (R-KY), Anna Eshoo (D-CA), John Joyce (R-PA), Jake Auchincloss (D-MA), and Mariannette Miller-Meeks (R-IA). The legislation codifies federal regulations permitting the reporting of multiple best price points for an outpatient drug, clarifies that the best price under a value-based arrangement is the price paid if all benchmarks are satisfied, and expands the use of value-based arrangements for drugs administered in an inpatient setting. AMCP strongly supports the passage of the MVP Act.

Visit AMCP's [Value in Medicaid page](#) for more information.



We are
MCPs.

The Real Cost of State Drug Importation Programs? Patient Safety.

On April 18, AMCP CEO Susan A. Cantrell, [APhA](#) CEO Michael D. Hogue, and [ASHP](#) CEO Paul W. Abramowitz penned a joint article in response to FDA's authorization of Florida's Agency for Health Care Administration's drug importation program. Authorized under section 804 of the Federal Food, Drug, and Cosmetic Act, the program allows the state of Florida to import certain prescription drugs from Canada. The article, published in [PharmExec.com](#), explains that international drug importation may increase the risk of U.S. citizens being exposed to unsafe medicines. "We have serious concerns that state importation programs open the door for unsafe drugs to enter the country, potentially endangering millions of Americans," the authors write. The U.S.' existing closed drug distribution system ensures that patients are protected from the risks posed by counterfeit and substandard drugs. The authors warn that Florida's importation program may bypass the rigorous FDA safeguards that guarantee the safety and efficacy of prescription drugs consumed domestically. Additionally, ongoing prescription drug shortages in Canada mean importation programs are unlikely to meet U.S. demand, thus reducing the prospect of meaningful drug price reductions for American consumers.

Read the [full article](#).

AMCP Comments on Medicare Prescription Payment Plan Model Documents

The Inflation Reduction Act (IRA) requires all Medicare prescription drug plans to offer enrollees the option to pay their out-of-pocket prescription drug costs in capped monthly increments, rather than in-full at the point-of-sale. Standalone Medicare prescription drug plans and Medicare Advantage plans with prescription drug coverage must fully implement the program by Jan 1, 2025. On Feb. 29, 2024, CMS released Model Documents regarding this program, known as the Medicare Prescription Payment Plan (MPPP), to provide standardized and consistent language for potential and active program participants. On April 29, AMCP provided comments in response to the Model Documents, which commend CMS for supporting plan sponsors in their efforts to implement the requirements of the MPPP. AMCP's comments also encourage CMS to further simplify the Model Documents' language to meet the needs of those with limited English proficiency or health literacy and suggest the development of education resources such as cost calculators to provide enrollees with further insight into the potential savings offered by the MPPP.



The image is a vertical banner for AMCP's 'Format for Formulary Submissions 5.0'. At the top, the AMCP logo is displayed in white on a dark blue background. Below the logo, a yellow banner reads 'NEWLY UPDATED'. The main title 'AMCP Format for Formulary Submissions 5.0' is centered in a large, bold, dark blue font. A prominent purple button with the word 'DOWNLOAD' in white is positioned below the title. At the bottom of the banner, there is a small image of the document cover, which features the title 'JMCP AMCP Format for Formulary Submissions 5.0' and a subtitle 'Guidance on Submission of Proposed and Proposed Clinical and Evidence Information and Evidence'.

Read AMCP's [Comment Letter](#).

AMCP Government Affairs Staff Make Headlines at AMCP 2024

Last month, thousands of managed care pharmacy professionals convened in New Orleans for [AMCP 2024](#). Among the many topics discussed during the meeting's Continuing Pharmacy Education sessions and keynotes, legislative and regulatory issues such as PBM legislation and biosimilar interchangeability were front and center. Ahead of the meeting, Jennifer Mathieu, Senior Vice President of Professional & Government Affairs at AMCP, sat down with *Managed Healthcare Executive* [to discuss AMCP's legislative priorities in 2024](#). These include the Access to Prescription Digital Therapeutics Act ([S.723/H.R. 1458](#)), Medicaid VBPs for Patients Act ([H.R. 2666/S. 4204](#)), Equitable Community Access to Pharmacist Services Act ([H.R. 1770/S. 2477](#)), and efforts to increase the uptake of biosimilar therapies. Adam Colborn, Director of Government Affairs at AMCP, [spoke with the American Journal of Managed Care](#) about biosimilar interchangeability and approaches to increase the uptake of these therapies. Colborn also [discussed current state-level Pharmacy Benefit Manager legislative and regulatory trends](#) with Managed Healthcare Executive, including transparency requirements, spread pricing and rebate pass-throughs, and copay limits and accumulators.

View more [media coverage from AMCP 2024](#).

AMCP | 675 North Washington Street, Suite 220 | Alexandria, VA 22314
You received this email because you are subscribed to Government and Advocacy from AMCP.
Update your [email preferences](#).